Christopher Dittus
Division of Hematology | Lymphoma Program Lineberger Comprehensive Cancer Center · UNC Lineberger Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher Dittus as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05498220 · Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell LymphomaUNC Lineberger Comprehensive Cancer Center · terminated · Diffuse Large B-cell Lymphoma · principal investigator
- Ph2NCT04548648 · A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS LymphomasUNC Lineberger Comprehensive Cancer Center · active not recruiting · Central Nervous System Lymphoma · principal investigator
- Ph1NCT02700022 · A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasUNC Lineberger Comprehensive Cancer Center · terminated · Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:33 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.J Clin Oncol · 2020320 citationsRCR 12.7
- A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.Blood · 201972 citationsRCR 2.3
- Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma.Blood Adv · 202246 citationsRCR 3.1
- Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study.Lancet Haematol · 202429 citationsRCR 3.3